Improvement of Platysma Prominence With OnabotulinumtoxinA: Safety and Efficacy Results From a Randomized, Double-Blinded, Placebo-Controlled Phase 3 Trial

Published: 15 October 2024| Version 1 | DOI: 10.17632/kdh5p39vsc.1
Contributors:
Sabrina Fabi, Shannon Humphrey, Brian Biesman, Rosalyn George, Brenda LaTowsky, Robert A. Weiss, Grace S. Park, Sandhya Shimoga, Elisabeth Lee, Edward Jierjian, Warren Tong, René Hopfinger

Description

These supplementary materials provide additional data supporting the main manuscript (OnabotA for Platysma Prominence Phase 3[309]) on the safety and efficacy of onabotulinumtoxinA for improving platysma prominence. They consist of a plain language summary, tables detailing the number of injections and total doses administered, participant demographics, baseline characteristics, efficacy results in the modified intent-to-treat population, and treatment-related adverse events in the safety population. Diagrams illustrating injection sites and participant flow in the study are also included.

Files

Categories

Botulinum Toxin, Neck, Face, Randomized Controlled Trial, Patient Satisfaction

Licence